Skip to content

Near-infrared Software Performance Study

Near-Infrared Software Performance Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02200458
Enrollment
62
Registered
2014-07-25
Start date
2012-11-30
Completion date
2014-12-31
Last updated
2015-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Access Complication

Brief summary

This study will look at the performance capabilities of software for VeinViewer.

Detailed description

This study will look at the performance capabilities of future software for VeinViewer.

Interventions

Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.

Sponsors

Christie Medical Holdings, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Must be 18 years of age or older 2. Must be considered to be in overall good health by investigator 3. Must pass all prescreening questions 4. Must be able to read and understand English

Exclusion criteria

1. Presence of tattoos, scarring, and/or extensive hair in the areas to be assessed for cannulation. 2. IV cannulation in the arms or hands in the previous 4 weeks.

Design outcomes

Primary

MeasureTime frame
Number of Participants for Whom Successful Visualization of Vasculature Was AchievedOne day

Countries

United States

Participant flow

Participants by arm

ArmCount
VeinViewer
Vascular imaging technology will be used to visualize peripheral vasculature. VeinViewer
62
Total62

Baseline characteristics

CharacteristicVeinViewer
Age, Continuous37.5 Years
STANDARD_DEVIATION 10.8
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
62 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Fitzpatrick20.2 Points
STANDARD_DEVIATION 7
Height168.7 CM
STANDARD_DEVIATION 10.5
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
53 Participants
Sex: Female, Male
Female
21 Participants
Sex: Female, Male
Male
41 Participants
Weight83.2 kg
STANDARD_DEVIATION 17.6

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 62
serious
Total, serious adverse events
0 / 62

Outcome results

Primary

Number of Participants for Whom Successful Visualization of Vasculature Was Achieved

Time frame: One day

ArmMeasureValue (NUMBER)
VeinViewerNumber of Participants for Whom Successful Visualization of Vasculature Was Achieved62 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026